Printer Friendly

Screening of thyroid dysfunction in pregnancy.

BACKGROUND

Thyroid diseases have a strong predominance in women of child bearing age. [1] Pregnancy produces an overall increase in thyroid activity, which allows the healthy individual to remain in a net euthyroid state. The prevalence of hypothyroidism is around 5 per 1000 in women and overt hypothyroidism is about 3/1000. The incidence of thyroid disease in pregnancy has been increasing in the last decade. This can have adverse effects on maternal and foetal health. [2] Many of these could be prevented or ameliorated by early detection and appropriate treatment. This will only be possible if we implement screening for thyroid function during pregnancy. Hypothyroidism in pregnant women has been associated with complications like preeclampsia, preterm labour and post-partum haemorrhage. For the babies too, there are risks of foetal distress and congenital abnormalities. [3]

Graves' hyperthyroidism can lead to miscarriage, abruptio placentae, preterm labour and preeclampsia.

Postpartum thyroid dysfunction occurs within the first year after delivery and can manifest as hyper or hypothyroidism.

MATERIALS AND METHODS

They study was conducted in the department of Obstetrics and Gynaecology at Govt. Medical College, Thrissur between January 2013 and January 2014. A total of 300 patients from antenatal clinics were included. It was a prospective study. All healthy pregnant women with no other medical disorders and singleton pregnancies were included. Those with documented thyroid disorders, medical disorders or hyperemesis were excluded. After detailed history and examination, free T3, free T4 and TSH estimation were done in the first trimester for all these patients using the ELISA method. Those with abnormal thyroid function were made to undergo thyroid antibody testing were treated and followed up till termination of pregnancy. For those with abnormal thyroid function, tests were repeated 6 weekly and drug doses titrated accordingly. They were followed up throughout pregnancy.

Maternal outcome was noted in terms of preeclampsia, abruptio placentae, anaemia, gestational diabetes, incidence of caesarean section and postpartum haemorrhage. The foetal outcome was noted in terms of birth weight, Apgar score at one minute, neonatal intensive care unit admission, preterm delivery, Intrauterine Growth Restriction (IUGR), foetal distress and intrauterine demise. Neonatal outcomes were noted in terms of hyperbilirubinaemia, respiratory distress, sepsis, hypoglycaemia, hypothermia, intracranial bleed, necrotising enterocolitis and early neonatal death. Neonatal thyroid function estimation was also done.

RESULTS

The patients were divided into five groups according to the thyroid function test results.

Group I - Euthyroid, defined as normal TSH.

Group II - Subclinical hypothyroidism, [4] defined as high TSH in presence of normal levels of free [T.sub.4].

Group III - Overt hypothyroidism, defined as high TSH with low free [T.sub.4].

Group IV - Overt hyperthyroidism defined as low TSH with raised free [T.sub.4].

Group V - Subclinical hyperthyroidism, defined as low TSH with normal free [T.sub.4].

Out of 300 patients, 25 (8%) had deranged thyroid function. Prevalence of hypothyroidism was 20 (6.6%), out of which 10 had overt hypothyroidism and 10 had subclinical hypothyroidism. One case of thyroid follicular carcinoma was detected in a case with overt hypothyroidism.

The prevalence of hyperthyroidism was 5 (1.6%), out of which all 5 were overt hyperthyroid. Anti-TPO (Thyroid peroxidase) and ATA (Thyroglobulin antibody) were done in patients with deranged TSH levels.

Anti-TPO antibody was found positive in 10 of the hypothyroid patients (4 overt and 6 subclinical). ATA was positive in 5 hypothyroid patients (3 subclinical and 2 overt). Both were raised in three cases of hypothyroidism (2 subclinical and 1 overt). Thyroid antibodies were found negative in all 5 cases of hyperthyroidism.

Euthyroid (275), Subclinical hypothyroidism (10), Overt hypothyroidism (10), Overt hyperthyroidism (5).

Adverse Maternal Effects

Adverse maternal effects in the hypothyroidism group, which were significant was preeclampsia.

Mode of Delivery

Regarding mode of delivery in the different groups, LSCS for foetal distress was done in 3 out of the total 10 cases of subclinical hypothyroidism, which was significant.

Foetal Outcomes

In the foetal outcome, adverse outcomes in overt hypothyroidism included 2 preterm births, 3 cases of IUGR (which was significant statistically), 2 cases of LBW (Low Birth Weight) and 2 cases of abortions. In the subclinical hypothyroidism group, there were 3 preterm births, 3 cases of IUGR, 1 case of LBW, 1 abortion and 1 still birth. No adverse outcomes were seen in the cases of hyperthyroidism.

Neonatal Outcomes

There were 3 cases of hyperthermia in the subclinical hypothyroid group, which was statistically significant; 1 case of RDS (Respiratory Distress Syndrome), 2 cases of low Apgar. In overt hypothyroid cases, there were 2 hyperthermia cases, 3 cases with low Apgar and 1 case of neonatal sepsis.

DISCUSSION

Assessment of thyroid function during pregnancy should be done with a careful clinical evaluation of the patients symptoms and measurement of TSH and free thyroid hormones. [5] Measurement of thyroid autoantibodies may be useful in selected cases to detect Graves' disease or Hashimoto's thyroiditis. [6,7] Various studies have shown that targeted thyroid function testing would miss about 1/3 of pregnant women with overt/subclinical hypothyroidism. [8] Thus it is best to screen for thyroid dysfunction early in the pregnancy and treatment started at the earliest.

CONCLUSION

Out of 300 patients, 25 had deranged thyroid function; 20 had hypothyroidism and 5 had hyperthyroidism. AntiTPO antibody was positive in 10 of the hypothyroid patients (4 overt and 6 subclinical). Preeclampsia was significantly high in the hypothyroid group. Foetal distress was more for the subclinical hypothyroid. Preterm births and IUGR were also common foetal outcomes in the hypothyroid group.

REFERENCES

[1] Goodwin TM, Montoro M, Mestman JH. Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects. Am J Obstet Gynecol 1992;167(3):648-52.

[2] Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21(10): 1081-125.

[3] Casey BM, Leveno KJ. Thyroid disease in pregnancy. Obstet Gynecol 2006;108(5):1283-92.

[4] Committee on Patient Safety and Quality Improvement. ACOG committee opinion no. 381: subclinical hypothyroidism in pregnancy. Obstet Gynecol 2007;110(4):959-60.

[5] Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin Endocrinol Metab 2007;92(1):203-7.

[6] Lazarus JH. Thyroid function in pregnancy. Br Med Bull 2011;97(1):137-48.

[7] Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Eng J Med 1999;341(8):549-55.

[8] Lazarus JH, Kaklamanou M. Significance of low thyroid-stimulating hormone in pregnancy. Current opinion in endocrinology diabetes and obesity 2007;14(5):389-92.

Seena K. B (1), Ajithkumar V. R (2)

(1) Assistant Professor, Department of Obstetrics and Gynaecology, Government Medical College, Thrissur.

(2) Assistant Professor, Department of Radiotherapy, Government Medical College, Thrissur.

Financial or Other, Competing Interest: None.

Submission 13-01-2017, Peer Review 06-02-2017,

Acceptance 13-02-2017, Published 06-03-2017.

Corresponding Author:

Dr. Seena K. B, Assistant Professor, Department of Obstetrics and Gynaecology, Government Medical College, Thrissur. E-mail: devu666@yahoo.co.in

DOI: 10.14260/jemds/2017/330
Table 1. Adverse Maternal Effects in various Groups

                 I (275)      II (10)    III (10)   IV (5)

Preeclampsia   15 (5.45%)    3 (30%) *   2 (10%)      --

  Abruptio      6 (2.18%)        0       1 (10%)      --
  Placenta

  Anaemia      15 (5.45%)        0       1 (10%)      --

Gestational    37 (13.45%)       1       2 (20%)      --
  Diabetes

 Postpartum    13 (4.73%)        0       1 (10%)      --
Haemorrhage

P < 0.009 (Gr I vs Gr II)

Table 2. Mode of Delivery in Different Groups

                       I           II         III     IV

     LSCS         86 (31:27%)    6 (60%)    3 (10%)   --

   LSCS for       10 (3.64%)    3 (30%) *   1(10%)    --
Foetal Distress

 Instrumental     18 (6.55%)     2 (20%)       0      --
   Delivery

    Normal            163        2 (20%)       7      5
    Vaginal

P < 0.002 (Gr I vs Gr II)

Table 3. Foetal Outcomes in various Groups

                 I           II         III      IV

 Preterm     57 (20.7%)    2 (20%)    3 (310%)   0
   IUGR      15 (5.45%)   3 (30%) *   3 (30%)    0
   LBW       20 (7.27%)    2 (20%)    1 (10%)    0
 Abortion    8 (2.91%)     2 (20%)    1 (10%)    0
Stillbirth   2 (0.73%)        0       1 (10%)    0

P < 0.029 (Gr I vs Gr II)

Table 4. Neonatal Outcomes in various Groups

                      I           II         III     IV

 Hyperthermia     10 (3.64%)   3 (30%) *   2 (20%)   0
      RDS          8 (2.9%)     1 (10%)       0      0
    Sepsis        7 (2.54%)        0       1 (10%)   0
Low Apgar Score   32 (11.6%)    2 (20%)    3 (30%)   0

P < 0.003 (Gr I vs Gr II)
COPYRIGHT 2017 Akshantala Enterprises Private Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Research Article
Author:Seena, K.B.; Ajithkumar, V.R.
Publication:Journal of Evolution of Medical and Dental Sciences
Article Type:Report
Date:Mar 6, 2017
Words:1408
Previous Article:A study of dysfunctional uterine bleeding--clinical factors and endometrial histology.
Next Article:Assessment of maternal and perinatal outcome in pregnancy beyond 40 weeks of gestation.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters